Donate to medical research: why choose the IHU ICAN?
Donate to medical research:
why choose IHU ICAN?
By making a donation to the ICAN IHU, you’ll be making a concrete contribution to research into cardiometabolic diseases, accelerating progress for the benefit of patients and combating the 1st cause of death in women and the 2nd cause of death in the general population in France.
IHU ICAN (Foundation for Innovation in Cardiometabolism and Nutrition) is a scientific cooperation foundation founded in 2011 by AP-HP, Inserm and Sorbonne University.
To help patients, support the 170 doctors and 230 researchers at IHU ICAN!
Why make an IFI donation to advance research?
We are all concerned by cardiometabolic diseases, which are metabolic diseases (familial hypercholesterolemia, obesity, fatty liver disease (FHLD), diabetes…) often complicated by cardiovascular disease.
• 140,000 people die every year from cardiovascular disease,
• 47% of the population is overweight,
• 17 million people suffer from high blood pressure,
• 4 million people are treated for diabetes.
Our research teams need the support of donors and sponsors to accelerate our ongoing innovative projects to improve understanding, treatment and prevention of these serious chronic diseases.
If you are subject to the IFI (Impôt sur la Fortune Immobilière), you can benefit from a tax advantage by making a donation to IHU ICAN. 75% of the amount of your donation is deductible from your IFI, up to an annual limit of €50,000.
Your donation also qualifies for tax deductions of up to 66% of its amount from Impôt sur le Revenu (IR) and 60% from Impôt sur les sociétés (IS).
Cardiometabolic diseases: research advances thanks to your donations!
Donations are used to develop forward-looking programs in priority areas:
- Imaging to find new biomarkers of metabolic diseases to improve prevention, diagnosis and monitoring of treatment efficacy,
- Health data, Artificial Intelligence (AI) and patient cohorts to build robust, collaborative and innovative research programs,
- The biology of cardiometabolic diseases and new interfaces (microbiota, fatty tissue, cholesterol, liver) to understand the mechanisms of development and progression of cardiometabolic diseases,
- Rare diseases to improve understanding of extreme and rare phenotypes.
Thanks to the generous support of IHU ICAN’s patrons, our researchers and physicians can carry out large-scale projects to better understand the interactions between organs, and develop precision medicine in cardiometabolism.
By 2023, IHU ICAN has raised €950,000 thanks to the generosity of its committed sponsors!
Sponsorship paves the way for a world first in heart transplantation
Thanks to the support of our patrons, the Pr Guillaume Lebreton (Cardiac surgeon, AP-HP, Hôpital de la Pitié-Salpêtrière, IHU ICAN) in Pr Pascal Leprince’s cardiac surgery department, achieved a world first in heart transplantation in January 2024 The 1st transplantation of a heart graft after transport across the Atlantic Ocean, with the heart preserved for more than 12 hours instead of the usual 4!
Our warmest thanks go to the Adicare association, Air France, Bouygues, XVIVO and all the collectors and donors of the 2023 Heroes’ Run for their invaluable commitment.
In a context of shortage of heart transplants, this success opens up major prospects for cardiac transplantation, by providing better access to hearts that are eligible today but unused, notably for reasons of distance and therefore transport time.
We need your help to go further!
Examples of large-scale projects to support
- ICONIC: the 1st atlas of cardiac and liver imaging in the general population
- PEGASE : pilot trial of heart transplantation after prolonged storage using an ex-vivo perfusion device
- The CHAIRE MASH, for innovative research, training and care projects on fatty liver disease
- MAESTRIA : the 1st digital platform for integrative diagnosis of atrial cardiomyopathy, using artificial intelligence
Contact us to find out more
Francine Trocmé, Communications and Sponsorship Director, f.trocme@ihuican.org
What are your donations for? Some equivalents
- 1,000€ = preparation of a biobank (cells, DNA, serum and plasma) from the blood donations of 5 patients for research into pathology-related markers
- 5,000€ = purchase of assay equipment for ICAN Biocell Human Liver Biology or ICAN Biocell iPS platforms
- 25,000€ = study of the effect of pharmacological drugs on fat depletion in isolated primary human hepatocytes, with a view to using them to save “steatotic” livers that are unsuitable for liver transplantation because of the shortage of grafts (5 independent experiments).
- 50,000€ = funding for one year of post-doctoral studies
- 120,000€ = funding of a 3-year thesis for a project to develop a relevant multi-organoid (heart-liver) model to study cardiometabolic diseases.
- 300,000€ = purchase of equipment to analyze candidate biomarkers and biomarkers of interest
- 1 0000 000€ = purchase of state-of-the-art equipment for metabolomics and lipidomics analyses
Fight against primary liver cancer of metabolic origin: the precious support of the Constance and Andrei Rhoe Foundation
Fight against primary liver cancer of metabolic origin: the precious support of the Constance and Andrei Rhoe Foundation
Primary liver cancer is the 6th most common cancer in terms of incidence and the 4th most common in terms of mortality worldwide.
The Constance and Andrei Rhoe Foundation has chosen to support the actions of the IHU ICAN, whose vocation is to fight against cardiometabolic diseases. This sponsorship will support research on the metabolic causes of liver cancer, and the training of young Romanian researchers and doctors in this field.
Learn about the study that will support this valuable donation to better understand the progression of NASH to primary liver cancer.
The commitment of the Constance and Andrei Rhoe Foundation
Sponsored by the Fondation de France, the Constance and Andrei Rhoe Foundation aims to support medical research projects in biology and biochemistry, in favour of the the fight against cancer, as well as projects in education, music, democracy and civic awareness.
Their founders have chosen to support the IHU ICAN through an annual grant over a period of 3 years. This will enable a Romanian doctoral student to carry out research on primary liver cancer as part of a multicenter study coordinated by Prof. Vlad Ratziu at the Pitié-Salpêtrière Hospital.
Main goals are:
- Identification of risk factorsfor primary liver cancer related to the metabolic syndrome,
- Estimating the prevalence of metabolic liver cancer in the French population,
- Estimation of temporal trends (incidence) of this condition over the past 10 years.
What you need to know about primary liver cancer
Primary liver cancer, also known as hepatocellular carcinoma, is one of the few cancers that is increasing. It occurs mainly in people who already have liver disease.
- 6th most common cancer in terms of incidence,
- 4th most frequent in terms of mortality in the world,
- An incidence that is increasing by 9% each year in the USA.
Hepatic consequence of the metabolic syndrome, metabolic steatosis has become the 1st cause of chronic liver disease, affecting 25-30% of the general adult population in its most frequent and least severe form. A progressive form of steatosis, metabolic steatohepatitiscan lead to hepatic fibrogenesis, resulting in liver cirrhosis.
This explains why the incidence of primary metabolic liver cancer has become the fastest growing indication for liver transplantation.
Unfortunately, primary liver cancers occurring in subjects with metabolic steatohepatitis are often detected at a later and therefore more advanced stage, which limits the possibilities of curative therapies.
It is therefore important today to better understand, identify and stratify :
- Mechanisms of carcinogenesis associated with the metabolic syndrome,
- The role of metabolic and inflammatory factors in the pathogenesis of primary liver cancer,
- Carcinological risk in subjects with metabolic syndrome,
- The circumstances of occurrence of primary liver cancer in a non-cirrhotic liver,
This is the objective of our study which will be conducted over a period of 3 years in 300 patients with primary metabolic liver cancer, using a multicenter cohort with a biobank.
The entire IHU ICAN team warmly thanks the Constance Foundation and Andrei Rhoe for their trust!
Your donations are essential to help the IHU ICAN fighting against cardiometabolic diseases.
Medtronic reinforces its support for medical research with the IHU ICAN!
Medtronic reinforces its support for medical research with the IHU ICAN!
Medtronic, a world leader in technologies, services and solutions for the medical sector, has decided to reinforce its support for the research work of the IHU ICAN by signing a 3-year agreement.
What types of work will this grant support? Discover below Medtronic’s commitment to medical research alongside the Pitié Salpêtrière Hospital’s rhythmology unit.
Why support medical research with the IHU ICAN?
Cardiometabolic diseases are the 1rst cause of chronic diseases and death in France (diabetes, obesity, liver disease or “NASH”, heart and vessel diseases…). They increase considerably from year to year, and impact the lives of millions of French people.
To fight against this scourge, the IHU ICAN is developing numerous research projects that require significant investments, and the commitment of our sponsors allows us to accelerate innovations for the benefit of patients.
The generosity of donors and sponsors is invaluable in improving the care of patients suffering from these chronic diseases, which often lead to episodes of aggravation and hospitalization.
Medtronic’s commitment to cardiometabolic diseases
Medtronic’s invaluable support of the IHU ICAN will contribute to the financing of ambitious work on:
- Arrhythmogenic cardiomyopathy,
- The study of the characteristics and impact of treatment of cardiac rhythm disorders by catheter ablation,
- Automated quantificationof subepicardial left atrial fat on CT and atrial strain on MRI in the ablation of atrial fibrillation…
Their donation will also support patient awareness actions with the creation of a website that will allow patients to find information on their pathology, treatments and ongoing research programs.
The entire IHU ICAN team warmly thanks Medtronic for its confidence!
Learn more about Medtronic’s commitment here.
